Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million
Aug 15 (Reuters) - Gilead Sciences (GILD.O) said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.
SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Tentarix Biotherapeutics LP, a biotechnology company developing first-in-class targeted, conditional antibody-based multifunctional biotherapies, today announced the formation of a Scientific Advisory Board (SAB) and appointments to its Board of Directors and leadership team.